Dupont Capital Management Corp Supernus Pharmaceuticals, Inc. Transaction History

Dupont Capital Management Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 29, 2020	SELL	$14.45 - $24.69 $272,382 - $465,406	-18,850 Closed	0 $0
Q4 2019 Jan 27, 2020	SELL	$19.93 - $29.13 $302,816 - $442,601	-15,194 Reduced 44.63%	18,850 $447,000
Q3 2019 Oct 28, 2019	SELL	$25.47 - $33.37 $92,965 - $121,800	-3,650 Reduced 9.68%	34,044 $936,000
Q4 2018 Feb 01, 2019	BUY	$30.84 - $49.51 $218,131 - $350,184	7,073 Added 23.1%	37,694 $1.25 Million
Q1 2018 May 02, 2018	BUY	$37.15 - $46.9 $828,259 - $1.05 Million	22,295 Added 267.78%	30,621 $1.4 Million
Q3 2017 Oct 31, 2017	BUY	$36.75 - $49.65 $305,980 - $413,385	8,326	8,326 $333,000

279

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.04B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.